Results 51 to 60 of about 32,506 (196)

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Tissue Characterization in Cardiac Amyloidosis

Biomedicines, 2022
Cardiac amyloidosis (CA) has long been considered a rare disease, but recent advancements in diagnostic tools have led to a reconsideration of the epidemiology of CA. Amyloid light-chain (AL) and transthyretin (ATTR) amyloidoses are the most common forms
Veronica Musetti, Francesco Greco, Vincenzo Castiglione, Alberto Aimo, Cataldo Palmieri, Dario Genovesi, Assuero Giorgetti, Michele Emdin, Giuseppe Vergaro, Liam A. McDonnell, Angela Pucci   +10 more
doaj   +1 more source

Systemic Amyloidosis – Insights by Cardiovascular Magnetic Resonance [PDF]

, 2015
Systemic amyloidosis is the exemplar infiltrative, extracellular disease. Although it is a multi-organ disorder, cardiac involvement drives prognosis. Survival is worst in the AL amyloidosis subtype. It can affect any age and any race. There is no direct
Banypersad, SM
core  

Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background The relationship between structural pathology and electrophysiological substrate in cardiac amyloidosis is unclear. Differences between light‐chain (AL) and transthyretin (ATTR) cardiac amyloidosis may have prognostic implications. Methods and
Michele Orini, Adam J. Graham, Ana Martinez‐Naharro, Christopher M. Andrews, Antonio de Marvao, Ben Statton, Stuart A. Cook, Declan P. O'Regan, Philip N. Hawkins, Yoram Rudy, Marianna Fontana, Pier D. Lambiase   +11 more
doaj   +1 more source

Misdiagnosis of hereditary amyloidosis as AL (Primary) amyloidosis [PDF]

, 2002
Background: Hereditary, autosomal dominant amyloidosis, caused by mutations in the genes encoding transthyretin, fibrinogen A -chain, lysozyme, or apolipoprotein A-I, is thought to be extremely rare and is not routinely included in the differential ...
Booth, D.R., Gilbertson, J.A., Hawkins, P.N., Booth, S.E., Lachmann, H.J., Gillmore, J.D., Bybee, A., Pepys, M.B.   +7 more
core  

Systemic amyloidosis in England: an epidemiological study. [PDF]

, 2013
Epidemiological studies of systemic amyloidosis are scarce and the burden of disease in England has not previously been estimated. In 1999, the National Health Service commissioned the National Amyloidosis Centre (NAC) to provide a national clinical ...
Smith, CJ, Banypersad, SM, Whelan, CJ, Venner, CP, Dungu, J, Pinney, JH, Lachmann, HJ, Taube, JB, Gillmore, JD, Gibbs, SD, Hawkins, PN, Wechalekar, AD   +11 more
core  

Baseline characteristics of patients with ATTR cardiac amyloidosis.

, 2021
Data are presented as percentages, as appropriate. Abbreviations: ATTR, transthyretin amyloidosis. (DOCX)
Zaza Iakobishvili (505022), Noa Rhurman-Shahar (11250356), Ashraf Hamdan (3579284), Osnat Itzhaki Ben Zadok (6235943), Mordehay Vaturi (11250350), Iuliana Vaxman (11250353), Ran Kornowski (540888)   +6 more
core   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
wiley   +1 more source

The value of screening biopsies in light chain (AL) and transthyretin (ATTR) amyloidosis [PDF]

, 2020
INTRODUCTION: Systemic amyloidosis is a histological diagnosis, often achieved via critical organ biopsy. Screening biopsies represent a low-risk approach to diagnosis.
Sharpley, F, Cohen, OC, Whelan, CJ, Fontana, M, Martinez-Naharro, A, Lachmann, HJ, Gillmore, JD, Sachchithanantham, S, Hawkins, PN, Gilbertson, JA, Wechalekar, AD, Mahmood, S   +11 more
core   +2 more sources